Spontaneous network activity of cerebellar granule neurons: impairment by in vivo chronic cannabinoid administration.
Synchronized activity of neuronal networks has been proposed to be essential for cerebellar function. To examine the occurrence and organization of spontaneous neuronal activity in the cerebellum in vivo, we imaged mouse cerebellar slices loaded with the intracellular Ca2+ concentration indicator, fura-2. Recordings were then analysed statistically to identify correlated network activity. Ca2+ imaging revealed consistent spontaneous correlated network activity of granule cells (GC), which often occurred in clusters of coactivated GC. The number of spontaneously active GC, their activation frequency and correlation, were controlled by glutamate and GABA ionotropic receptors. These findings indicate that distinctive patterns of correlated activity between GC networks may be relevant for cerebellar circuit function. Cannabinoid antagonist-precipitated delta9-tetrahydrocannabinol (THC) withdrawal impaired motor coordination. Given that the cerebellum has been suggested recently to be a main substrate for cannabinoid withdrawal, we used imaging of spontaneous network activity to examine whether GC, which contain CB1 cannabinoid receptors, respond to chronic THC treatment and withdrawal. Acute administration of THC had no effect on patterns of spontaneous GC network activity. In contrast, chronic THC administration severely impaired GC activity and network coordination. Incubation of cerebellar slices, from chronically THC-treated mice, with the cannabinoid antagonist, SR141716A increased the number and network correlation of active GC. These data provide physiological evidence of the involvement of cerebellar circuits in the adaptive changes occurring during chronic THC exposure and withdrawal.
Ghozland
Sandy
S
Laboratory of Neuropharmacology, University Pompeu Fabra, Barcelona 08003, Spain.
Aguado
Fernando
F
Espinosa-Parrilla
Juan F
JF
Soriano
Eduardo
E
Maldonado
Rafael
R
D000818:Animals; D002186:Cannabinoids / Q000378:metabolism / Q000494:pharmacology*; D002531:Cerebellum / Q000166:cytology* / Q000187:drug effects* / Q000502:physiology; D013759:Dronabinol / Q000494:pharmacology*; D066298:In Vitro Techniques; D051379:Mice; D009415:Nerve Net / Q000187:drug effects* / Q000502:physiology; D009474:Neurons / Q000187:drug effects* / Q000502:physiology; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000037:antagonists & inhibitors / Q000502:physiology; D013375:Substance Withdrawal Syndrome / Q000503:physiopathology; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology
D002186:Cannabinoids; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; D013759:Dronabinol